Modulators of β-amyloid peptide aggregation comprising...

Details Modulators of β-amyloid peptide aggregation comprising... Modulators of β-amyloid peptide aggregation comprising...

2007-02-13

2007-02-13

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

C424S001210, C424S009450, C436S501000, C514S018700, C530S330000

Reexamination Certificate

active

10677076

ABSTRACT:
Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3–5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

REFERENCES:
patent: 4119493 (1978-10-01), Isowa et al.
patent: 5338663 (1994-08-01), Potter et al.
patent: 5470951 (1995-11-01), Roberts
patent: 5541290 (1996-07-01), Harbeson et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5817626 (1998-10-01), Findeis et al.
patent: 5854204 (1998-12-01), Findeis et al.
patent: 5854215 (1998-12-01), Findeis et al.
patent: 5985242 (1999-11-01), Findeis et al.
patent: 6120768 (2000-09-01), Griffiths et al.
patent: 6277826 (2001-08-01), Findeis et al.
patent: 6303567 (2001-10-01), Findeis et al.
patent: 6319498 (2001-11-01), Findeis et al.
patent: 6610658 (2003-08-01), Findeis et al.
patent: 6689752 (2004-02-01), Findeis et al.
patent: 6831066 (2004-12-01), Findeis et al.
patent: 0554887 (1993-08-01), None
patent: 0681844 (1995-11-01), None
patent: 0641881 (2003-04-01), None
patent: WO-93/04194 (1993-03-01), None
patent: WO-95/07093 (1993-03-01), None
patent: WO-93/11772 (1993-06-01), None
patent: WO-94/28412 (1994-12-01), None
patent: WO-95/05394 (1995-02-01), None
patent: WO-95/05604 (1995-02-01), None
patent: WO-95/08999 (1995-04-01), None
patent: WO-95/12815 (1995-05-01), None
patent: WO-95/20979 (1995-08-01), None
patent: WO-96/28471 (1996-09-01), None
patent: WO-97/21728 (1997-06-01), None
patent: WO-98/08868 (1998-03-01), None
Barrow, Colin J. and Michael G. Zagoraki (1991) “Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition”Science253: 179-182.
Barrow, Colin J. et al. (1992) “Solution Conformations and Aggregational Properties of Synthetic Amyloid β-Peptides of Alzheimer's Disease: Analysis of Circular Dichroism Spectra”J. Mol. Biol.225: 1075-1093.
Brown, Abraham M. et al. (1994) “Biotinylated and Cysteine-Modified Peptides as Useful Reagents for Studying the Inhibition of Cethepsin G”Analytical Biochemistry217: 139-147.
Burdick, Debra et al. (1992) “Assembly and Aggregation Properties of Synthetic Alzheimer's A4/β Amyloid Peptide Analogs”Journal of Bilological Chemistry267(1): 546-554.
Chantry, Andrew et al. (1992) “Biotinyl Analogues of Amylin as Biologically;Active Probes for Amylin/CGRP Receptor Recognition”FEBS295(2): 123-127.
Clements, Angela et al. (1993) “Aggregation of Alzheimer's Peptides”Biochemical Society Transactions22: 169.
Clemens, J.A.et al. (1992) “Implants Containing β-Amyloid Protein Are Not Neurotoxic to Young and Old Rat Brain”Neurobiology of Aging13: 581-586.
Come, Jon H. et al. (1993) “A Kinetic Model for Amyloid Formation in the Prion Diseases: Importance of Seeding”Proc. Natl. Acad. Sci. USA90: 5959-5963.
Evans, Krista C. et al. (1995) “Apolipoprotein E Is a Kinetic But Not e Thermodynamic inhibitor of Amyloid Formation: Implications for the Pathogenesis and Treatment of Alzheimer Disease”Proc. Natl. Acad. Sci. USA92: 763-767.
Fabian, Heinz et al. (1993) “Comparative Analysis of Human and Dutch-Type Alzheimer β-Amyloid Peptides by Infrared Spectroscopy and Circular Dichroism”Biochemical and Biophysical Research Communications191(1): 232-239.
Fabian, Heinz et al. (1994) “Synthetic Post-Translationally Modified Human Aβ Peptide Exhibits a Markedly Increased Tendency to Form β-Pleated Sheets in vitro”Eur. J. Biochem.221: 969-964.
Flood, J. et al. (1994) “Topography of a Binding Site for Small Amnestic Peptides Deduced from Structure-activity Studies: Relation to Amnestic Effect of Amyloid β Protein,”PNAS, 91:380-4.
Fraser, Paul E. Et al. (1994) “Conformation and Fibrillogenesis of Alzheimer Aβ Peptides with Selected Substitution of Charged Residues”J. Mol. Biol.244: 64-73.
Fraser, Paul E. et al. (1992) “Fibril Formation by Primate, Rodent, and Dutch-Hemormagic Analogues of Alzheimer Amyloid β-Protein”Biochemistry31: 10716-10723.
Gorevic, PD et al. (1967) “Ten to Fourteen Residue Peptides of Alzheimer's Disease Protein are Sufficient for Amyloid Fibril Formation and Its Characteristic Xray Diffraction Pattern”Biochemical and Biophysical Reaearch Communications147(2): 854-862.
Gowing, Eric et al. (1994) “Chemical Characterization of Aβ 17-42 Peptide, a Component of Diffuse Amyloid Deposits of Alzheimer Disease”J. Biol. Chem.269(15): 10987-10990.
Halverson, Kurt et al. (1990) “Molecular Determinants of Amyloid Deposition In Aizheimer's Disease: Conformational Studies of Synthetic β-Protein Fragments”Biochemistry29(11): 2639-2644.
Hansen, Morten B. et al. (1989) “Re-examination and Further Development of a Precise and Rapid Dye Method for Measuring Cell Growth/Cell Kill”J. Immunol. Meth.119: 203-210.
Hardy, John A. and Gerald A. Higgins (1992) “Alzheimer's Disease: The Amyloid Cascade Hypothesis”Science256: 184-185.
Handrix, Julia et al. (1992) “A Convergent Synthesis of the Aryload Protein of Alzheimer's Disease”J. Am. Che. Soc.114: 7930-7931.
Hilbich, Caroline et al. (1991) “Aggregation and Secondary Structure of Synthetic Amyloid βA4 Peptides of Alzheimer's Disease”J. Mol. Biol.218: 149-163.
Hilbich, Caroline et al. (1991) “Human and Rodent Sequence Analogs of Alzheimer's Amyloid βA4 Share Similar Properties and Can Be Solubilized In Buffers of pH 7.4”Eur. J. Biochem.201: 61-69.
Inouye, H. et al. (1993) “Structure of β-Crystallite Assemblies Formed by Alzheimer β-Amyloid Protein Analogues: Analysis by X-ray Diffraction,”Biophys. J.64: 502-19.
Isowa, Yoshikazu et al. (1977) “The Synthesis of Peptides of Means of Protsolytic Enzymes”Bulletin of the Chemical Society of Japan50: 2762-2765.
Jarrett, Joseph T. and Peter T. Lansbury, Jr. (1993) “Seeding ‘One-Dimensional Crystallization’ of Amyloid: A Pathogenic Mechanism in Alzheimer's Disease and Screpia?”Cell73: 1055-1058.
Jarrett, Joseph T. et al. (1993) “The Carboxy Terminus of the β Amyloid Protein Is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesia of Alzheimer's Disease”Biochemistry32(18): 4693-4697.
Katakai, Ryoichi (1977) “Sequential Polypeptides. The Steric Hindrance of L-Valine Residues In the Polycondensation of Peptide Active Estera”Bulletin of the Chemical Society of Japan50(5): 1173-1178.
Kelly, Jeffery W. and Peter T. Lansbury, Jr. (1994) “A Chemical Approach to Elucidate the Mechanism of Transthyretin and β-Protein Amyloid Fibril Formation”Int. J. Exp. Clin. Invest1: 186-205.
Kirschner, Daniel A. et al. (1987) “Synthetic Peptide Homologous to β Protein from Alzheimer Disease forms Amyloid-like Fibrils In vitro”Proc. Natl. Acad. Sci. USA84: 6953-6957.
Klunk, William E. and Jay W. Pettegrew (1990) “Alzheimer's β-Amyloid Protein

Affiliated with

Also associated with

Rating

Modulators of β-amyloid peptide aggregation comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulators of β-amyloid peptide aggregation comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of β-amyloid peptide aggregation comprising... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3885476